Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Modifiedsierra health and lifePolicy 2026T0126TT

Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation

Defines and summarizes multiple noninvasive and implantable electrical stimulation and neuromodulation therapies for pain, rehabilitation, and neuromuscular restoration, and reviews evidence for specific nervous system conditions such as spinal cord injury and cerebral palsy; intended for clinicians and policy reviewers.

Policy Summary

Payersierra health and life

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation

Policy CodePolicy 2026T0126TT

Change TypeCode list update & template revision

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionWhen requesting implantable neurostimulation, obtain prior authorization documenting diagnosis, prior conservative therapies, and measurable treatment goals.

SourceLink

POLICY UPDATE CHANGES

Added CPT code 64567 to the list of applicable CPT codes.

Removed temporary code 0720T from the list of applicable CPT codes.

Created shared policy version to support application to Oxford plan membership.

Archived previous policy version 2025T0126SS.

1CPT code added

1CPT code removed

~14distinct therapies defined

777largest pooled study sample

1,115RCT participants (post-stroke foot drop meta)

Coverage Criteria and Evidence Summaries

Indication-specific evidence summaries

Evidence-based coverage considerations by indication and modality (narrative findings extracted):

Home-based FES for SCI: Insufficient and unclear peer-reviewed evidence to support home-based FES for rehabilitation following spinal cord injuryevidence insufficient

Hayes EARB concluded no/unclear support

FES for cardiorespiratory fitness in SCI: Hybrid FES cycling shows moderate improvements in V̇o2peak vs arm crank ergometry in small studiessmall studies, heterogeneity

Máté et al. systematic review found moderate effect but limited by small sample sizes

NMES/FES for muscle hypertrophy in SCI:

Policy Summary

Payersierra health and life

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation

Policy CodePolicy 2026T0126TT

Change TypeCode list update & template revision

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionWhen requesting implantable neurostimulation, obtain prior authorization documenting diagnosis, prior conservative therapies, and measurable treatment goals.

SourceLink

On This Page

Systematic review reported average 26% increase in muscle cross-sectional area and variable changes in lean mass across studies

Bekhet et al. concluded robust hypertrophy but recommended larger RCTs

FES cycling long-term effects in chronic SCI: Cohort study reported improved neurological scores, increased muscle mass and strength, reduced fat, and improved QOL with long-term FES cycling compared to ROM/stretchingsingle-center nonrandomized data

Sadowsky et al. 2013

ES superimposed on PRT for quadriceps strength in SCI: Small RCT showed increased voluntary strength but uncertain clinical importance and unclear contribution of ES vs PRT alonesmall RCT

Harvey et al. 2010

FES for cerebral palsy gait improvement: Mixed evidence: RCT cross-over found FES not superior to AFO (Moll 2023); other small studies and meta-analysis suggest improvements in walking speed and step length (Zhu 2022)heterogeneous small studies

Patient selection and follow-up important

Coverage considerations and evidence synthesis

Evidence-supported and coverage-relevant considerations summarized from multiple systematic reviews and RCTs

Indications with some supportive evidence: Foot drop and hemiplegic gait post-stroke and ankle dorsiflexor weakness in children/adolescents with CP have multiple RCTs and systematic reviews reporting improvements in ankle dorsiflexion angle, gait kinematics, and sometimes walking speed or step length when FES is used (often in combination with supervised therapy)

Benefits vary by device type, timing (acute/subacute vs chronic), and whether FES is combined with supervised exercise

Circumstances where benefit is more likely: When FES is applied as part of supervised, repeated training protocols (e.g., sessions multiple times per week) and/or combined with physical therapy, studies report better outcomes than unsupervised use; some meta-analyses show gait speed improved when FES is combined with supervised exercise

See da Cunha et al. and multiple HTAs

Uncertain or limited benefit: Evidence is low-to-moderate quality overall with heterogeneity; several HTAs concluded no clear improvement in some functional or QOL measures versus AFOs or conventional therapy, especially in chronic stroke populations

Matsumoto et al. (2023) showed no significant improvement in 6MWT in a Japanese sample

Postoperative NMES for quadriceps strengthening

Covered when ALL of the following are met (examples supported by RCT evidence in this section):

Postoperative quadriceps NMES (TKA/ACL): NMES initiated early postoperatively (e.g., within 48 hours for TKA) as adjunct to standard rehabilitation with documented baseline and follow-up strength/functional measurestiming as reported

RCTs show early and sustained improvements in quadriceps strength and functional measures through one year, most pronounced early after surgery (Stevens-Lapsley et al., 2012).

FES for chronic heart failure

Considered for symptomatic chronic heart failure when used as an alternative or adjunct training modality and when supervised programs are not feasible:

FES for CHF patients: FES of the legs to improve peak VO2, 6-minute walk distance, and QOL compared with control in multiple RCTs and meta-analysesclinical stability (NYHA II-III) as in trials

Traditional exercise rehabilitation may outperform FES for some outcomes; benefits include reduced HF-related hospitalizations in one trial (Kadoglou et al., 2017).

Neurologic rehabilitation (MS, stroke) with FES/NMES

Use for neurologic indications (MS, stroke) — evidence and considerations:

FES for MS-related foot drop: FES can improve walking speed, duration, perceived exertion and some HRQOL domains, with effect sizes similar to AFOs in low-quality studies; further high-quality RCTs recommendeddocument gait impairment/foot drop and prior trials of orthoses if applicable

Body of evidence rated low quality due to small studies and heterogeneity.

FES cycling in sub-acute stroke/brain injury: Short-duration FES cycling (4 weeks) added to standard therapy did not improve mobility in a small RCT; strength effects uncleardocument sub-acute acquired brain injury and baseline mobility limitations

Clinical significance limited without mobility gains.

FES assist cycling in severe MS: Pilot data show higher VO2 with FES assist cycling vs voluntary cycling but clinical significance unknownN/A

Small pilot study; interpret cautiously.

ICU rehabilitation

ICU and critical illness applications — trial findings:

FES-assisted cycling in mechanically ventilated ICU patients: Large RCT found no improvement in physical disability at six months; no differences at ICU dischargetargeted to patients with anticipated long ICU stays as in trial

Higher-than-expected mortality and single-center design noted limitations.

Early in-bed cycling plus ES in critically ill adults: RCT showed no improvement in global muscle strength at ICU discharge and no differences at six monthsapplied early in ICU as in trial

No benefit compared to standardized early rehabilitation.

Musculoskeletal perioperative NMES

Musculoskeletal and perioperative uses supported by trials:

NMES for enhanced recovery after THR: Pilot and feasibility RCTs report reduced early postoperative pain during mobilization, reduced limb swelling/edema in some measures, and potential DVT prophylaxis signalsapplication per trial protocols (multiple short sessions over days post-op)

Studies limited by small size and short follow-up; further research recommended.

NMES to prevent quadriceps weakness after ACL reconstruction: Small RCTs show attenuation of strength loss and maintenance of muscle activation compared to shamearly post-op application and home-based adherence as per trials

Small sample sizes; clinical relevance needs further study.

Pediatric CP — NMES adjunct to casting

Pediatric (cerebral palsy) application:

NMES during serial casting for diplegic CP: Randomized trial showed NMES during serial casting preserved dorsiflexor and knee extensor strength and improved gait scores versus casting alone8-week intervention combined with physical therapy as trialled

Small pediatric RCT supporting adjunctive NMES to reduce strength loss during casting.

Musculoskeletal - Postoperative NMES

Evidence-based scenarios where NMES showed benefit

TKA quadriceps NMES: NMES applied early (initiated 48 hours after primary unilateral total knee arthroplasty), twice daily at maximum tolerable intensity for early quadriceps strengthening and functional improvementtreatment started 48 hours post-op; twice daily sessions; outcomes assessed through 52 weeks

RCT showed clinically meaningful improvements especially within first month and persisting at one year

Pediatric Cerebral Palsy - NMES adjunctive use

NMES used as adjunct to casting, strengthening, or gait training in children with spastic CP

NMES with serial casting: NMES applied during serial casting to preserve strength and improve gait outcomesstudies used 8-week interventions; applied through cast windows in some trials

Randomized trial favored NMES plus casting for strength and gait

NMES-assisted strengthening/gait: NMES combined with therapeutic exercise or gait practice to improve muscle volume, strength and gait parametersprogram durations varied (4–48 weeks; average 14 weeks), both home and professionally applied

Systematic reviews indicate potential benefits but recommend further research to define protocols

Cerebrovascular Accident (Stroke) - NMES applications

NMES has been studied for limb motor recovery, dysphagia, spasticity, and combined therapies post-stroke

NMES for dysphagia: NMES combined with swallowing therapy can improve swallowing function and quality of life and reduce complications in post-stroke dysphagiatreatment courses ranged 2–12 weeks; subgroup benefits noted with onset <20 days and age >60; some analyses favored <=4 week courses

Meta-analyses included large pooled samples (e.g., 46 RCTs, 3,346 participants) but heterogeneity and reporting of adverse events were limitations

NMES for upper/lower limb motor recovery: NMES, including CCFES and cyclic NMES, has shown variable benefits for ADLs and motor outcomes depending on timing (subacute), severity (severe paresis), and modalitystudies varied from subacute to chronic stages; some RCTs used 3-week to 12-week protocols

Systematic reviews and RCTs report potential ADL improvements but mixed effects on motor ability; CCFES may outperform cyclic NMES in some chronic-hand studies

Respiratory - NMES for COPD on Mechanical Ventilation

NMES applied during mechanical ventilation in COPD patients

NMES during mechanical ventilation: NMES applied to ventilated COPD patients may shorten mechanical ventilation duration and improve functional independence (bed-to-chair) at dischargeevidence from 4 RCTs totaling 144 adults on ventilatory support

Small number of heterogeneous trials; further high-quality studies recommended

Neurologic recovery (stroke)

Evidence summaries (no explicit unconditional coverage statements in this excerpt).

Stroke upper extremity NMES: Single-blinded RCT (Lin et al.) showed three weeks of NMES (30 min, 5 days/week) improved motor recovery vs control with benefits persisting at 3 and 6 months but study lacked sham control and had small sample.

Supports potential benefit but limited by study design and size.

Respiratory system / COPD

Respiratory/COPD evidence — mixed and generally low quality.

NMES in COPD on mechanical ventilation: Meta-analysis (Gutiérrez-Arias et al.) of 4 RCTs (n=144) suggests NMES may improve functional independence and reduce mechanical ventilation time, but heterogeneity and small study numbers limit conclusions.

Further robust RCTs recommended.

NMES vs usual care in severe COPD: Systematic review (Wu et al.) found insufficient evidence of benefit for HRQoL and peak exercise measures; overall evidence very low quality.

NMES should not replace pulmonary rehabilitation.

NMES effects on quadriceps and exercise outcomes: Cochrane review (Hill et al.) found NMES alone increased quadriceps force/endurance and 6-minute walk distance but evidence quality low/very low due to bias and small studies.

Potential short-term physiologic benefits with low-quality evidence.

ICU and perioperative muscle preservation

ICU, perioperative and miscellaneous hospitalized populations — heterogeneous results.

Hospitalized/ICU NMES: Systematic reviews/meta-analyses and RCTs show small-to-moderate effects on muscle strength, walking performance, and muscle size; some trials report reduced ventilation time and ICU/hospital length of stay while others show no functional improvement—study heterogeneity and risk of bias are frequent limitations.

Evidence promising for muscle preservation but inconsistent for functional outcomes.

Swallowing and stroke rehabilitation guidance

Swallowing disorders and stroke rehab guidance.

NMES for dysphagia: Systematic reviews report no firm evidence of efficacy; NICE recommends only using transcutaneous NMES for oropharyngeal dysphagia within research/audit arrangements due to limited and low-quality evidence.

Clinical use should follow governance/research frameworks.

NMES combined with therapy for spasticity: AHA/ASA states NMES combined with therapy may improve spasticity but insufficient evidence that NMES improves functional gait or hand use.

May be considered for spasticity but not demonstrated to improve key functional outcomes.

Interferential therapy for low back and musculoskeletal pain

Interferential therapy / IFC for musculoskeletal pain and low back pain.

IFT for NSCLBP: Systematic review/meta-analysis reported moderate-quality evidence that IFT probably reduces pain intensity and disability immediately post-treatment versus placebo, but not at intermediate follow-up; treatment heterogeneity noted.

Short-term benefit supported; longer-term effect uncertain.

IFT vs other electrotherapies: Trials comparing IFT and TENS show similar analgesic efficacy; overall evidence limited by small sample sizes and protocol heterogeneity.

IFT may be an option among electrotherapies for short-term pain relief.

Knee osteoarthritis (IFC)

Knee osteoarthritis and IFC evidence.

IFC for knee osteoarthritis: Systematic review/meta-analysis of 10 RCTs (n=493) found significant short-term and some long-term pain improvements and short-term function improvements with IFC versus control, but heterogeneity and risk of bias limit certainty; no obvious adverse effects reported.

IFC may improve pain and short-term function; larger high-quality trials needed.

Coverage evidence groups

Evidence-summary driven coverage considerations

IFT for knee osteoarthritis: Randomized trials and meta-analyses report short-term and some long-term pain and short-term function improvements for IFC/IFT in knee OA, but evidence is heterogeneous and guideline bodies (NICE) recommend against routine use due to insufficient consistent benefit

Sources: systematic reviews/meta-analyses and NICE guidance

IFT/IF for other musculoskeletal pain (shoulder, myofascial, LBP): Trials show mixed results: some RCTs show benefit versus low-current TENS or control in specific studies (e.g., Burch 2008 for knee combined IF/patterned stimulation; some shoulder and masticatory studies), while larger syntheses found no clear additional benefit versus standard care or other modalities; heterogeneity and small trial sizes limit conclusions

See Hussein 2021, Tugay & Kul 2023, Yu 2015

MENS (microcurrent) for masticatory/myofascial pain and acute knee pain: Small meta-analyses report modest pain reductions versus sham in masticatory myofascial pain; single RCTs show trends for improved pain/function in acute knee pain; overall evidence limited by small sample sizes and short follow-up

Further high-quality trials recommended

Evidence-based coverage considerations

Evidence summary and implied coverage stance based on available studies

Short-term perioperative/postoperative analgesia: TEAS/TEAS studies and meta-analyses report reduced pain scores and reduced opioid consumption within first 24-72 hours after surgery and reduced postoperative nausea/vomiting in some analysesshort-term (24-72 hours)

Multiple RCTs and meta-analyses show statistically significant but sometimes marginal clinical benefit

Adjunctive use with rehabilitation for low back pain: Some retrospective and controlled studies report reduced pain and disability when FSM/PENS is added to active rehabilitation, but evidence is limited and retrospective designs limit conclusionsup to 90 days reported

Authors call for randomized placebo-controlled trials

Knee osteoarthritis / acute knee pain: Small RCTs of MET/MENS report reduced evening pain and some functional improvement over short-term follow-up; studies are small and need confirmationweeks (2-4)

Authors recommend larger trials with longer follow-up

Chronic neuropathic pain and neuralgias: Single-arm and observational studies report pain reductions lasting up to months after PENS in small samples, but studies are non-randomized and limitedup to 6 months in observational follow-up

Evidence quality is low to moderate; results should be interpreted cautiously

Not established for long-term benefit: Multiple systematic reviews and trials report immediate or short-term effects but note lack of long-term follow-up and heterogeneity of protocols, limiting conclusions about sustained benefitlong-term (beyond 3 months) evidence lacking

Further high-quality, multicenter RCTs recommended

Evidence-derived coverage considerations

Evidence and guideline-derived considerations for coverage decisions

PENS for general pain indications: Evidence is mixed: small RCTs and observational studies report short-term pain reduction in some conditions (e.g., neuropathic pain, post-operative settings) but high-quality, long-term RCT evidence is limited; NICE recommends against PENS for low back pain/sciatica; AAN/AANEM/AAPMR endorse consideration of PENS for painful diabetic neuropathy.N/A

Use guideline-specific exclusions (e.g., LBP per NICE) when forming coverage policy.

PENFS for pediatric functional GI disorders: Multiple prospective and registry studies (including a 292-child registry) report short-term improvements in abdominal pain, nausea, and functional disability; however, many studies are open-label, single-center, lack controls, and have short follow-up; ECRI and Hayes assessments find evidence insufficient or no/unclear support for some GI indications (IBS/IB-Stim).N/A

Consider requiring RCT-level evidence or insurer-specified criteria for coverage.

PNS for postoperative knee pain/TKA and other peripheral indications: A multicenter double-blind RCT reported 60% of PNS subjects achieving ≥50% pain reduction vs 24% placebo for persistent post-TKA pain with leads left in 8 weeks; other small studies and retrospective series report functional improvement and opioid reduction for saphenous-targeted PNS but limitations include small sample sizes and heterogeneous populations.≥50% pain reduction during treatment phase used as responder definition in trials

Trials often used an 8-week lead dwell period and follow-up to 12 months for responders; require documentation of indication, target nerve, and trial response.

Evidence-based coverage considerations

Evidence summary-based stance and expected coverage considerations

PNS evidence: Available evidence for percutaneous and implantable peripheral nerve stimulation is low-quality and heterogeneous; some small RCTs, case series and systematic reviews report pain reduction and decreased opioid use but are insufficient to draw definitive efficacy conclusions.evidence quality low

Hayes, ECRI, and systematic reviews cite need for larger RCTs and better patient selection data

PEMF/PES evidence: PEMF/PES trials show mixed results with some short-term benefit for pain and function in knee OA and postoperative settings but heterogeneous protocols and limited long-term data.variable

AAOS downgraded recommendation to Limited for knee OA PEMF device due to access and evidence concerns

Restorative neurostimulation evidence: Restorative neurostimulation has prospective trial data with multi-year follow-up suggesting clinically meaningful improvements in pain, disability, and quality of life for selected refractory mechanical CLBP patients, but limitations include lack of controls and follow-up attrition.moderate

Long-term follow-up reported clinically significant improvements and opioid reductions

Restorative neurostimulation — evidence characterization

Evidence summary and implied coverage stance based on available studies

Restorative neurostimulation evidence: Available evidence includes one randomized double-blind sham-controlled trial (Gilligan 2021) and multiple observational follow-ups reporting improvements in pain, disability, and quality of life in selected cohorts but with limitations such as small sample sizes, high attrition, lack of long-term controlled comparisons, risk of bias, and explant rates.

Results show some durable improvements in responders but overall evidence considered insufficient/inconclusive by HTA bodies.

Key limitations: Limitations across studies include lack of independent active comparators, high attrition/explant rates, single-center designs, heterogeneous populations, and potential selection bias in follow-ups.

ECRI and Hayes assessments cite high risk of bias and recommend more independent studies.

Scrambler therapy — evidence and guideline conclusions

Scrambler therapy evidence and guideline positions

Scrambler therapy evidence: Multiple small RCTs, single-arm studies, and systematic reviews report short-term pain reductions and some secondary benefits, primarily for neuropathic pain (notably CIPN), but overall study quality is low and results are inconsistent across trials and indications.

Meta-analyses report marginal pain decrease post-treatment; methodological limitations common.

Guideline stance: ASCO states no recommendation outside clinical trials for CIPN due to low strength of evidence; ESMO/EONS/EANO gives a D grade and does not recommend ST for CIPN.

Guideline recommendations advise against routine clinical use for CIPN.

Scrambler therapy (CIPN) coverage criteria

Guideline-based coverage considerations for scrambler therapy in CIPN

Scrambler therapy for CIPN: Coverage for scrambler therapy for chemotherapy-induced peripheral neuropathy is not supported by major oncology guidelines due to low or inconsistent evidence; outside clinical trials it is not recommended.

ASCO found insufficient evidence; ESMO/EONS/EANO gave D rating indicating moderate evidence against efficacy or for adverse outcomes.

TLNS/PoNS coverage considerations

Translingual stimulation / PoNS (TLNS) evidence context

Evidence summary for TLNS/PoNS: Randomized trials and RCTs show potential improvements in gait/balance when TLNS/PoNS is combined with targeted physical therapy, but overall evidence is inconclusive due to small sample sizes and methodological limitations.

Multiple RCTs including Ptito et al., Tyler et al., and Hou et al. report improvements but call for larger trials and note limitations.

Restorative neurostimulation coverage criteria

Restorative neurostimulation (ReActiv8) indication

ReActiv8 implantable device: Indicated for bilateral stimulation of L2 medial branch for adults with intractable chronic low back pain associated with multifidus dysfunction who have failed prior therapy including medications and physical therapy and are not candidates for spine surgery.

Device has PMA approval (June 16, 2020).

Coverage guidance (none in this excerpt)

No explicit coverage criteria are provided in this section; it focuses on device clearances and bibliographic references.

Regulatory and evidence statements: This excerpt documents FDA clearances/approvals for Scrambler Therapy (ST MC-5A/ST-5A) and PoNS TLS, and notes that TENS devices are FDA Class II with multiple product codes; it does not define medical necessity or coverage decision logic.

Use other policy sections for coverage criteria.

Hayes' Evidence Analysis Research Brief concluded there is not enough published peer‑reviewed literature to evaluate home‑based functional electrical stimulation (FES) for rehabilitation after spinal cord injury (SCI). The brief reviewed limited abstracts (including one RCT reported across abstracts and one single‑arm study) and found no clinical position statements or guideline support, therefore the evidence for home‑based rehabilitative FES in SCI is insufficient and may be excluded on evidence grounds.

The policy excerpt does not list prescriptive procedural exclusions by device model or manufacturer, but multiple HTAs and systematic reviews emphasize heterogeneity across devices, small study sizes, variable stimulation parameters, and limited long‑term follow‑up. Because of these limitations, the evidence cautions against generalizing results from prototype, implanted‑electrode, or single‑device studies to broader populations; coverage decisions should not assume device‑specific positive findings apply universally without indication‑specific, higher‑quality evidence.

Randomized trials in critically ill, mechanically ventilated or ICU populations (for example, FES‑assisted cycling and early in‑bed cycling plus quadriceps ES) did not demonstrate improvements in long‑term physical disability or global muscle strength at discharge or six months in the cited RCTs. Therefore, routine use of FES/NMES in ICU patients to improve long‑term disability is not supported by the RCT evidence cited.

A systematic review of RCTs for masticatory muscle spasticity in cerebral palsy found only three small trials (botulinum toxin, functional training, and NMES) with very low certainty evidence. The authors concluded there is insufficient evidence to support NMES (or botulinum toxin) for masticatory spasticity in CP; clinical decisions should be individualized and informed by limited, low‑certainty data.

NICE guidance on knee osteoarthritis reviewed electrotherapy evidence and concluded that transcutaneous NMES should not be offered for people with knee OA because the evidence is inconsistent, mostly from small trials, and insufficient to demonstrate clinical benefit.

NICE explicitly reviewed interferential therapy (IFT/IFC) across musculoskeletal indications and found insufficient evidence to support its use. The guideline states IFT should not be offered for knee osteoarthritis, for chronic primary pain, and for low back pain with or without sciatica because clinical benefit is not established.

Evidence syntheses for percutaneous electrical nerve stimulation (PENS) in chronic low back pain report a very low quality evidence base with small trials and limited follow‑up. As a monotherapy for chronic low back pain, PENS yields very low‑quality evidence and is not recommended as a definitive treatment based on current data.

NICE guidance on TENS, PENS and IFT for low back pain and sciatica concluded there is insufficient evidence of clinical benefit and recommended that PENS (and related modalities) should not be offered for low back pain with or without sciatica.

Assessments of percutaneous and implantable peripheral nerve stimulation (PNS) identify a limited and heterogeneous evidence base. Reviews and HTAs found few high‑quality studies and concluded that implantable peripheral nerve stimulators and some commercial PNS systems (for example, systems without peer‑reviewed outcomes) lack robust evidence to support broad clinical use.

Major oncology guideline panels reviewed scrambler therapy for chemotherapy‑induced peripheral neuropathy (CIPN) and found the evidence insufficient and inconsistent. ASCO does not recommend scrambler therapy for CIPN outside clinical trials, and the ESMO/EONS/EANO guideline assigned a D rating, indicating the therapy is generally not recommended.

Because major guideline groups (ASCO; ESMO/EONS/EANO) recommend against routine use of scrambler therapy for CIPN or recommend it only in trial settings, scrambler therapy for CIPN is generally not recommended and would be excluded from routine coverage outside clinical trials per those guideline positions.

The excerpt does not list device‑specific or indication‑specific exclusions as explicit, but documents FDA clearances and device classifications (for example, Scrambler/ST device 510(k) clearances and TENS product codes). Coverage exclusions are derived from the evidence summaries and guideline recommendations rather than device regulatory status alone.

This Medical Policy is informational and must be applied in the context of the member's specific benefit plan. In the event of any conflict between this policy and the member specific benefit plan document, the member specific benefit plan governs and its terms control coverage decisions.

The policy identifies several therapies for which there is insufficient published literature to support routine coverage — for example, home‑based FES for SCI — and notes that such low‑evidence indications may be excluded from coverage absent stronger peer‑reviewed evidence.

Device and Procedure Coding

FES devices (FDA product code)mixed

GZI	FDA product code referenced for FES devices

NMES devices (FDA product code)mixed

IPF	FDA product code referenced for NMES muscle rehabilitation devices

Interferential Therapy devices (FDA product code)mixed

LIH	FDA product code referenced for Interferential Therapy devices

PES devicesmixed

PES	Pulsed Electrical Stimulation devices (product search reference)

Percutaneous/Peripheral Nerve Stimulation and PENS (FDA product code)mixed

NHI	FDA product code referenced for PNS and PENS devices

Peripheral Subcutaneous Field Stimulation / Peripheral Nerve Field Stimulation (FDA product code)mixed

PZR	FDA product code referenced for PSFS / PNFS devices (510k)

TENS / MENS / Scrambler devices (FDA product codes)mixed

GZJ	FDA product code referenced for MENS/TENS and Scrambler Therapy devices
NUH	FDA product code referenced for some TENS devices
NGX	FDA product code referenced for some TENS devices

Restorative Neurostimulation (FDA product code)mixed

QLK	FDA product code referenced for ReActiv8 implantable neurostimulation (PMA)

FDA product codes referencedmixed

GZJ	FDA product code referenced for TENS / related devices
NUH	FDA product code referenced for TENS / related devices
NGX	FDA product code referenced for TENS / related devices

Scrambler Therapy product codemixed

GZJ	FDA product code for Scrambler Therapy devices (Product Code GZJ referenced for ST-5A)

Applicable CPT code updatesCPT

64567	Added to applicable CPT codes
0720T	Removed from applicable CPT codes

inv-65: Study treatment duration/adherence

Typical trial/course lengthReported device treatment courses varied; example summary value cited as 14 weeks in study summaries (varies by study)

Adherence monitoringDevice usage adherence was monitored in trials (example: mean 94% adherence reported in Ptito et al.)

Session frequency examplesProtocols included twice-daily in-clinic/home sessions and daily sessions in some RCTs; specific schedules varied by study

Follow-up intervalsStudies reported follow-up assessments during treatment and up to months/years after (examples include 3‑ and 12‑week, and multi‑year follow-ups)

Prior Authorization, Documentation, and Workflow

Prior Authorization

Prior authorization recommended for implantable neurostimulation

Prior authorization is recommended for implantable neurostimulation systems (including implanted peripheral nerve stimulators and restorative neurostimulation devices such as ReActiv8). Requests should document diagnosis, prior conservative therapy, and treatment goals to support medical necessity and device selection.

Applicable devices: implanted PNS systems, restorative neurostimulation (ReActiv8), implantable lead systems
Reference device clearance/approval: ReActiv8 PMA (Product Code QLK)

Documentation Required

Prior authorization: indicate diagnosis, prior conservative therapy, and goals

Prior authorization requests must indicate the working diagnosis, duration and specifics of prior conservative management (e.g., physical therapy, medications, orthoses), documented functional impairment, and explicit, measurable treatment goals.

Specify phase of recovery, prior treatments and duration (e.g., ≥90 days for restorative neurostimulation)
State measurable goals (pain reduction, functional improvement, PRO/ODI changes)

Prior Authorization

Prior authorization recommended for low-evidence indications

For indications supported by limited or heterogeneous evidence (for example, many uses of PENS, some PNS indications, PEMF/PES, scrambler therapy), prior authorization is advisable to ensure appropriate patient selection and documentation of rationale.

Examples: PENS for LBP/sciatica (NICE advises against routine use), scrambler therapy for CIPN (guideline discouragement)
Provide rationale, prior treatment failures, and supporting literature when seeking authorization

Prior Authorization

Prior authorization recommended for NMES

Prior authorization is recommended for NMES/NMES-related programs when used beyond routine rehabilitation — include indication, targeted muscle groups or function, planned treatment duration, and measurable outcomes in the request.

Document NMES protocol details: electrode location, frequency/intensity, session duration and schedule
State baseline and planned follow-up objective measures (strength, gait speed, swallowing scores, 6MWD, etc.)

Prior Authorization

NMES for dysphagia — special governance

NICE guidance indicates that transcutaneous NMES for oropharyngeal dysphagia should be used only with special arrangements for clinical governance, consent, audit or research; prior authorization or research governance documentation may be required.

Provide documentation of clinical governance arrangements, informed consent process, and plan for audit or research when requesting authorization for NMES for dysphagia

Documentation Required

Prior auth: trial-phase response and targeted nerve

For peripheral nerve stimulation intended to address persistent postoperative pain or when a device trial phase precedes permanent implantation, prior authorization should document the trial-phase response, targeted nerve(s), and the magnitude/duration of benefit observed.

Include trial stimulation reports: lead placement, targeted nerve (e.g., femoral, sciatic, saphenous), percent pain reduction, functional change, and duration of response
For permanent implants, include evidence of successful trial and rationale for permanent device

Prior Authorization

Prior authorization for ReActiv8 (restorative neurostimulation)

Prior authorization for ReActiv8 (restorative neurostimulation) should document that the patient meets device indication criteria: intractable chronic low back pain associated with multifidus dysfunction, failure of conservative therapy (≥90 days including at least one course of physical therapy), and that the patient is not a surgical candidate.

Cite ReActiv8 PMA and indication (Product Code QLK)
Provide prior conservative management documentation (≥90 days) and objective measures (ODI, VAS)

Denial Risk

Evidence insufficiency for home-based FES in SCI

Evidence for home-based FES in spinal cord injury rehabilitation is insufficient in recent reviews; authorization requests for home-based FES should include strong supporting rationale and may be denied when peer-reviewed evidence is lacking.

Hayes EARB (2024) found insufficient peer-reviewed literature to support home-based FES for SCI
Include functional baseline, planned supervision, and monitoring if requesting coverage

Denial Risk

Evidence quality and standardization concerns may trigger denial

Low-quality, heterogeneous, or nonstandardized evidence (small studies, variable protocols, limited follow-up, and inconsistent adverse event reporting) may trigger denial for certain ES therapies. Provide high-quality supporting evidence and standardized treatment protocols when available.

Common concerns: heterogeneous stimulation parameters, lack of blinding, small sample sizes, limited long-term outcomes
Submit peer-reviewed RCTs or HTAs when available to support requests

Denial Risk

Evidence limitations may trigger denial

Where the evidence base is limited or inconsistent (for example, PENS for low back pain, PNS for many chronic pain etiologies, PEMF/PES), coverage may be denied absent adequate documentation of prior treatments and measurable expected benefit.

NICE guidance: PENS not recommended for LBP/sciatica (2016, updated 2022)
ECRI/Hayes assessments note insufficient evidence for many PNS and restorative neurostimulation indications

Denial Risk

NICE: PENS not recommended for LBP/sciatica

NICE updated guidance recommends against offering PENS for low back pain with or without sciatica due to insufficient and low-quality evidence; authorization requests for PENS for LBP/sciatica should reference this guidance and will be reviewed accordingly.

If requesting PENS for LBP/sciatica, provide high-quality evidence and rationale for deviation from NICE guidance

Denial Risk

Guideline-based denial risk for scrambler therapy

Major guideline panels do not recommend scrambler therapy for chemotherapy-induced peripheral neuropathy or other neuropathic pain outside clinical trials; requests for scrambler therapy should be supported by compelling clinical rationale and trial participation when applicable.

ASCO and ESMO guidance advise against routine use of scrambler therapy for CIPN outside trials
Hayes systematic review (2023) found evidence low or very low quality

Note

This section cites FDA 510(k) clearances

Scrambler therapy has received FDA 510(k) clearances for specific devices (e.g., Calmare/ST MC-5A and successors), but regulatory clearance alone does not imply coverage; clinical evidence and guideline recommendations will guide authorization decisions.

Device clearances: Scrambler Therapy devices (Product Code GZJ), TENS devices (GZJ/NUH/NGX), PoNS De Novo
Include device model and regulatory status in authorization requests

Documentation Required

Required clinical documentation for postoperative NMES

Required clinical documentation for postoperative NMES/NMES-like interventions should include indication, timing relative to surgery, rehabilitation plan, NMES parameters, and objective outcome measures to justify use and duration.

Example: NMES initiated 48 hours post-TKA with frequency/intensity, session schedule, and plan for objective strength and function reassessment
Document expected duration and stopping rules if no improvement

Documentation Required

Treatment parameters and duration documentation

Treatment parameters and planned duration should be documented (e.g., session frequency, intensity, electrode placement, total weeks of therapy) since study outcomes often depend on specific dosing and timing.

Provide protocol details: number of sessions/week, minutes per session, stimulation amplitude/frequency, supervised vs home-based
Indicate objective milestones and planned reassessment intervals

Documentation Required

Required supporting evidence

When applicable, include supporting evidence with authorization requests: RCTs, systematic reviews/HTAs, and device-specific clinical trial reports that demonstrate benefit for the requested indication.

Cite high-quality sources (e.g., Hayes HTAs, ECRI assessments, RCTs) relevant to the indication
Explain how the patient's presentation aligns with populations studied

Documentation Required

Supporting clinical documentation

Provide supporting clinical documentation such as trial reports, supervised rehabilitation program details (duration, number of supervised sessions), baseline symptom scores, and prior therapy failures when requesting coverage for implantable or extended neuromodulation therapies.

Include baseline PROs (VAS, ODI), prior nonoperative treatments and durations, and any imaging or physiologic testing supporting target selection
Document prior response to conservative care and reason for escalation to device therapy

Documentation Required

Conservative Therapy and Step Therapy Expectations

Consider trial of conservative transcutaneous or percutaneous modalities before implantable neurostimulation when clinically appropriate.

Conservative modalities trial: Consider noninvasive or minimally invasive therapies (eg, TENS, PENS, supervised therapeutic exercise) before implantable neurostimulation where clinically appropriate

Reflects conservative-first approach described in systematic reviews and guidelines

Trial of AFO or supervised exercise prior to FES is recommended by evidence syntheses as a comparator and reasonable step

AFO or supervised exercise trial: Demonstrate prior trial of ankle‑foot orthosis (AFO) or supervised exercise/physical therapy before authorizing assistive or rehabilitative FES for foot dropdocumented prior conservative management

Meta-analyses show AFO and FES provide similar improvements in walking speed; use of FES with supervised exercise may offer added benefit

Trial of orthosis or standard rehab may be considered prior to FES where applicable.

Orthosis or rehab trial: For MS-related foot drop and similar indications, consider trial of orthotic management (AFO) or standard rehabilitation before FESdocumented prior conservative management

HTAs and systematic reviews emphasize comparable benefits between AFO and FES in some outcomes

Demonstrate attempted or concurrent conventional therapy as applicable

Document prior/concurrent therapy: Document attempted or concurrent standard rehabilitation (eg, PT, OT, swallowing therapy) when requesting NMES/FES as adjunctive therapy

Many trials paired electrical stimulation with supervised rehabilitation; documentation aligns requests with study contexts

Consider standard rehabilitation/exercise as first-line before neuromodulatory electrotherapies

Standard rehab first-line: For COPD, NSCLBP and similar conditions, pulmonary rehabilitation or exercise-based programs should be considered first-line; NMES/IFT should not replace standard programs

Systematic reviews recommend NMES as adjunct, not replacement, of pulmonary rehabilitation

Trial of guideline-recommended conservative therapies prior to considering electrotherapy is expected.

Guideline-recommended conservative therapy trial: Require trial of guideline-recommended nonpharmacologic therapies (exercise, multidisciplinary rehab) prior to electrotherapy in chronic conditions

ACP and NICE guidance emphasize conservative-first approaches

Consider prior trial of active rehabilitation before adjunctive electrical stimulation coverage

Active rehabilitation trial: Consider requiring a prior trial of active rehabilitation (eg, minimum 30 days or equivalent supervised sessions reported in some studies) before approving adjunctive electrical stimulationminimum 30 days reported in FSM study

Many studies used stimulation as an adjunct to active therapy rather than as sole therapy

Failure of conservative multimodal pain management prior to consideration

Conservative multimodal failure: For PNS/PENS and implantable modalities, require documented failure of multimodal conservative pain management prior to consideration

Trials frequently enrolled patients refractory to multiple non-surgical treatments

Document prior conservative therapies and refractory status

Document prior therapies: Document prior nonoperative treatments attempted (eg, medications, injections, PT), baseline symptom scores, and evidence of refractory status when requesting device-based therapies

Supports reviewer assessment of appropriateness and aligns with trial inclusion criteria

Document prior medical management and physical therapy attempts

>90 days prior management: For restorative neurostimulation candidate selection, document >90 days of medical management and at least one attempt of physical therapy prior to implantation>90 days

Reflects eligibility criteria used in RCTs (Gilligan et al.).

Documented prior physical therapy and failed conservative management before considering implantable restorative neurostimulation; PoNS/TLNS trials typically include concurrent PT.

PT and failed conservative care documented: For implantable restorative neurostimulation, document prior PT and failed conservative management; for PoNS/TLNS, trials combined device use with targeted PT so documentation of prior PT or plateau with PT is expected

Aligns with trial contexts and device indications

This section does not specify conservative therapy requirements prior to neuromodulation; it provides device regulatory context and evidence citations.

Regulatory context: Some device-specific summaries describe regulatory clearances but do not define universal conservative-therapy prerequisites; follow device labeling and plan-specific rules

Use clinical criteria and prior-auth guidance for coverage decisions

Before applying this policy, check the member specific benefit plan and applicable mandates; policy use is informational and must be aligned with plan-specific coverage rules.

Verify plan and mandates: Confirm member-specific benefit plan terms and applicable federal/state mandates before applying coverage criteria; in case of conflict, the member specific benefit plan governs

Policy is informational and must be aligned with plan-specific rules

Treatment Frequency, Duration, and Limits

inv-168: Not specified in this section; studies used variable session numbers and durations.

Frequency limits statedNot specified in this section; studies used variable session numbers and durations

Study heterogeneityIFC/IFT and related trials reported varied treatment durations and follow-up intervals across RCTs and systematic reviews

Policy implicationNo explicit policy frequency caps provided in excerpt; reviewers should reference individual trial protocols when assessing requests

inv-169: PENS / MET / TEAS — studies used varied session counts

Session counts reportedStudies ranged from single-session protocols up to multi-session courses (examples: single treatment sessions; up to 16 sessions reported)

Course examplesExamples include 10 sessions over 3 weeks, weekly x3 sessions, and other multi-week schedules depending on trial

Outcome timingMost PENS/MET/TEAS trials measured immediate or short-term outcomes; long-term effects generally not established

inv-170: Percutaneous Peripheral Nerve Stimulation (PNS) — temporary lead durations reported

Temporary lead dwell durationsReported temporary lead durations include leads left in place for eight weeks in randomized trials

Short-course PNS examplesSome PNS trials used treatment periods up to ~60 days (e.g., 8‑week lead dwell observed) before lead removal or assessment

Permanent implantsPermanent PNS implants are described separately and follow different implantation and follow-up protocols

inv-171: Percutaneous PNS implantation/trial — procedural and temporal trial details

Trial-phase procedure detailsPNS trials commonly involved percutaneous lead placement adjacent to targeted peripheral nerves followed by a multi-week treatment/trial period (e.g., 8 weeks) to assess response

Responder criteria in trialsResponder definitions often used ≥50% pain reduction during the treatment phase as a success threshold

Follow-up and crossoverPlacebo-controlled crossover designs allowed sham participants to cross over to active PNS with similar lead dwell/removal schedules

inv-172: Restorative neurostimulation (implant) — implantation schedules and follow-up intervals

Implantation and activation scheduleRestorative neurostimulation (eg, ReActiv8) implants deliver scheduled stimulation twice daily; pivotal trials used a therapy period with activation and follow-up assessments over months to years

Candidate selection timingTrials required prior conservative management (≥90 days medical management and at least one attempt of physical therapy) before implantation

Long-term follow-upDevice studies reported multi-year follow-ups (examples: 3‑ and 5‑year observational follow-ups documented) to assess durability

inv-173: TLNS/PoNS treatment courses and adjunctive PT

Treatment course rangesTLNS/PoNS trials reported courses ranging from 5 weeks (in-clinic/short programs) up to 14 weeks (including home-based components)

Concurrent therapyTrials combined TLNS/PoNS with targeted physical therapy; device use was adjunctive rather than standalone in RCTs

Adherence loggingSome trials logged device adherence automatically (example: mean 94% adherence reported in Ptito et al.)

inv-174: No frequency limits specified for Scrambler, TENS, or TLS devices in this excerpt.

Frequency limits in policy excerptNo frequency limits specified for Scrambler, TENS, or TLS/PoNS devices in this excerpt

Typical treatment patternsScrambler protocols in trials commonly used daily sessions (~30–50 minutes) over ~10 working days; TENS/TLS schedules varied by device and indication

Reviewer actionBecause no policy frequency caps are stated, reviewers should reference device-specific trial protocols and plan-specific rules when assessing requests

Definitions and Device Descriptions

inv-120: Neuromuscular Electrical Stimulation (NMES) — definition and intent

DefinitionTranscutaneous application of electrical currents to cause muscle contractions intended to promote reinnervation, prevent or retard disuse atrophy, relax muscle spasms, and promote voluntary muscle control.

Clinical intentUsed for muscle strengthening, prevention of atrophy, rehabilitation after neurologic injury or surgery, swallowing therapy, and ICU muscle preservation in selected protocols.

Typical deliveryDelivered via surface electrodes applied to target muscle groups; protocols vary in session duration, intensity, and frequency per indication/trial.

inv-121: Percutaneous Electrical Nerve Stimulation (PENS) — definition

DefinitionMinimally invasive pain treatment using acupuncture-like needles connected to an external power source inserted percutaneously near the painful area; electrodes are not permanently implanted.

Mechanism/targetsPlacement is percutaneous (near area of pain) rather than cutaneous; theorized to modulate hypersensitivity and pain pathways potentially via endogenous opioid-like mechanisms.

Typical study parametersStudies include single to multiple treatment sessions; many trials assessed immediate or short-term pain outcomes rather than long-term durability.

inv-122: Percutaneous Electrical Nerve Field Stimulation (PENFS) — definition

DefinitionA variation of percutaneous stimulation that uses low-frequency current to stimulate a general area (eg, auricular/peripheral cranial neurovascular bundles) rather than a single peripheral nerve, intended to modulate central pain pathways.

Common usesOften applied in auricular/peripheral field applications and pediatric functional GI disorders (PENFS); evidence includes registry and small controlled studies.

Evidence characteristicsPublished studies are often small, open-label, or registry-based with limited long-term controlled data; quality of evidence is generally limited.

inv-123: Percutaneous Peripheral Nerve Stimulation (PNS) — definition

DefinitionNeuromodulation with electrode(s) implanted or placed adjacent to a peripheral nerve to deliver impulses that disrupt pain signal transmission.

Temporary vs permanentPNS can be delivered via temporary percutaneous leads (trial phases of weeks) or permanent implants depending on indication and response.

Evidence summaryEvidence is heterogeneous: some RCTs report clinically meaningful pain reductions (eg, ≥50% responders in TKA PNS trial), but overall quality is limited and larger RCTs are needed.

inv-124: Peripheral Subcutaneous Field Stimulation (PSFS) — definition

DefinitionElectrode arrays implanted in subcutaneous tissue of a painful area targeting cutaneous nerve endings when anatomic nerve targets are not well defined.

Distinguishing featureUnlike PNS, PSFS/PNFS targets a broader subcutaneous field rather than a specific named peripheral nerve.

Evidence baseUsed in select case series and trials, often as adjunct to other neuromodulation strategies; evidence quality varies.

inv-125: Restorative Neurostimulation — definition (eg, ReActiv8)

DefinitionImplantable stimulation targeting the multifidus/paraspinal muscles (eg, ReActiv8) intended to rehabilitate neuromuscular control in mechanical chronic low back pain.

Device exampleReActiv8 Implantable Neurostimulation System — PMA-approved device for bilateral L2 medial branch stimulation in selected patients.

Clinical intentAims to restore motor control and reduce disability in refractory CLBP associated with multifidus dysfunction after failure of conservative care.

inv-126: Transcutaneous Electrical Nerve Stimulation (TENS) — definition

DefinitionSurface electrodes deliver current to decrease pain perception by inhibiting afferent pain impulses and/or stimulating endorphin release; distinct from muscle‑stimulating NMES devices.

Regulatory statusClass II FDA‑regulated devices with multiple product codes (eg, GZJ, NUH, NGX) referenced for TENS family devices.

Typical usesCommonly used for symptomatic pain relief across musculoskeletal and neuropathic conditions; protocols and evidence quality vary widely.

inv-127: Functional Electrical Stimulation (FES) — definition

DefinitionUse of electrical stimulation to elicit functional movements (eg, improve ambulation in foot drop) and for task‑oriented training (eg, FES cycling) to augment voluntary movement.

Assistive vs rehabilitativeFES may be applied as assistive (immediate gait support) or rehabilitative (training aimed at lasting motor recovery); evidence differs by application.

Common indicationsFoot drop post‑stroke, CP gait assistance, SCI cycling; RCTs often small and variable in protocols and outcomes.

inv-128: Assistive vs Rehabilitative FES — definition and distinction

Assistive FESProvides immediate functional support during activities (eg, foot drop correction during walking).

Rehabilitative FESAims for motor recovery through repeated stimulation and training, with potential for lasting improvement beyond device use.

Evidence nuanceRCTs/meta-analyses show FES can improve ankle dorsiflexion and some gait parameters; benefits for activity/participation are less certain and depend on combination with supervised therapy.

inv-129: NMES — definition and clinical intent

NMES overviewTranscutaneous stimulation applied to elicit muscle contractions to improve strength, prevent disuse atrophy, or aid rehabilitation in selected populations.

Clinical applicationsUsed for ICU muscle preservation, postoperative quadriceps strengthening, dysphagia treatment, and neurologic recovery in stroke/CP/SCI contexts.

Evidence considerationsEvidence quality varies by indication; many trials small and heterogeneous—document treatment parameters and outcomes when seeking coverage.

inv-130: FES — functional electrical stimulation definition

FES definitionFunctional electrical stimulation applied in a task-oriented manner to augment voluntary movement and improve cardiopulmonary or functional outcomes.

Typical deliveryTargeted stimulation of motor nerves/muscles timed with functional tasks (eg, dorsiflexion during gait).

Comparative evidenceWhen combined with supervised exercise, FES may improve gait speed versus supervised exercise alone in some trials; standalone superiority is inconsistent.

inv-131: NMES — neuromuscular electrical stimulation definition (additional reference)

NMES (transcutaneous) summaryTranscutaneous electrical stimulation applied to muscle groups to elicit contractions to improve strength, function, or reduce spasticity.

Typical protocolsSession durations and frequencies vary by indication (eg, 20–60 minutes daily for weeks in perioperative or stroke trials).

Outcome measuresStudies report outcomes such as muscle strength, gait kinematics, FMA scores, and ADLs; improvement magnitude depends on timing and combination with therapy.

inv-132: CCFES — Contralaterally controlled functional electrical stimulation definition

CCFES definitionContralaterally controlled functional electrical stimulation — a method where stimulation to the paretic limb is controlled by activity of the contralateral (unaffected) limb to promote functional use.

Clinical useStudied in subacute and chronic post‑stroke upper limb rehabilitation with multi‑week programs (eg, 3–12 weeks) showing variable benefit versus cyclic NMES.

Outcome nuanceSome trials showed improved manual dexterity vs cyclic NMES in certain subgroups; generalizability requires further study.

inv-133: Interferential Therapy (IFT/IFC) — definition

IFT/IFC definitionAn electrotherapy modality generating beat-frequency currents (interferential/IFC) intended to reduce pain and improve function in musculoskeletal conditions.

Evidence profileSystematic reviews report short-term pain relief versus placebo for some indications but heterogeneity and limited long-term benefit noted.

Typical trialsTrials include variable durations and comparisons to TENS, placebo, or standard care; methodological quality varies.

inv-134: NMES — transcutaneous stimulation applied to muscle groups (definition variant)

NMES muscle contraction goalTranscutaneous stimulation applied to muscle groups to elicit contractions with the goal of improving strength, preventing atrophy, and aiding rehabilitation.

ApplicationsUsed across ICU, perioperative, neurologic, and musculoskeletal rehabilitation contexts with protocol variability across studies.

DocumentationTrials frequently document baseline and follow-up strength/functional measures—such documentation is recommended for coverage requests.

inv-135: Interferential current therapy (IFC/IFT) — definition (additional)

IFC/IFT additional noteInterferential current therapy uses medium-frequency interfering currents aiming to reduce pain; evidence shows short-term effects but limited long-term data.

ComparatorsCompared to TENS and placebo in trials; no consistent superiority over other electrotherapies was established across reviews.

Clinical implicationMay be considered for short-term pain relief in selected patients, but guideline groups (eg, NICE) recommend caution for certain indications.

inv-136: Microcurrent electrical nerve stimulation (MENS/MCT/FSM) — definition

MENS definitionMicrocurrent electrical nerve stimulation (MENS/MCT/FSM) uses very low‑amplitude currents applied transcutaneously to modulate pain and promote healing.

Study dosing examplesTherapy durations in trials ranged from days to weeks (eg, 3 hours/day over 4 weeks in Lawson et al.; 10 sessions over 3 weeks in Ranker et al.).

Evidence strengthSmall RCTs/meta-analyses suggest short-term pain benefit in select conditions (eg, masticatory myofascial pain), but larger trials are needed.

inv-137: TEAS — transcutaneous electrical acupoint stimulation definition

TEAS definitionTranscutaneous electrical acupoint stimulation — noninvasive electrical stimulation of acupuncture points used perioperatively and for pain modulation.

Perioperative useSystematic reviews of TEAS/TEAS report reduced opioid consumption and short-term pain reductions in many RCTs; protocols vary by acupoint selection and timing.

Evidence considerationsHeterogeneity of protocols and moderate risk of bias in many trials limit strength of conclusions despite consistent short-term analgesic signals.

inv-138: PENS — percutaneous needle/probe-based stimulation definition

PENS (needle-based) definitionPercutaneous needle or probe-based electrical stimulation applied to peripheral nerves or tissues for pain control; electrodes are not permanently implanted.

ApplicationsStudied for musculoskeletal pain, postoperative analgesia, and neuropathic pain with mixed short-term effects and limited long-term RCT data.

Protocol variabilityTrials vary widely in session counts (single to multiple), stimulation parameters, and anatomical targets—standardization lacking.

inv-139: MENS / MET / FSM — microcurrent/electro‑microcurrent definitions

Microcurrent variantsMENS / MET / FSM denote microcurrent or frequency‑specific microcurrent therapies delivering very low intensity currents for pain and healing applications.

Clinical evidenceSmall RCTs show mixed results across indications (eg, knee pain, myofascial pain); overall evidence insufficient for broad conclusions.

Typical dosingTreatment schedules in trials ranged from multiple sessions over 1–4 weeks to daily multi‑hour applications depending on study design.

inv-140: PENS — percutaneous needle/probe-based stimulation definition

PENS applicationPercutaneous electrical stimulation applied to peripheral nerves for pain management; some trials used electroacupuncture or intramuscular stimulation variants.

Evidence limitationsMany PENS studies are small with heterogeneous methods; meta-analyses suggest immediate/short-term effects but limited long-term evidence.

Clinical guidanceSome guideline bodies (eg, NICE) advise against offering PENS for low back pain/sciatica due to insufficient evidence for routine use.

inv-141: PENFS — auricular or field-based percutaneous stimulation definition

PENFS definitionAuricular or field‑based percutaneous stimulation targeting nerve fields (eg, external ear) thought to modulate central pain pathways; often studied in pediatric GI disorders.

Study typesIncludes registries and prospective observational studies as well as some controlled trials; evidence often limited by open‑label design.

Typical durationsTherapy courses in registries often span up to 12 weeks of consecutive therapy with follow-up surveys at weeks and months post‑therapy.

inv-142: PNS — percutaneous leads adjacent to peripheral nerves definition

PNS definitionPercutaneous leads placed adjacent to specific peripheral nerves (eg, femoral, sciatic, saphenous) to deliver stimulation aimed at reducing chronic peripheral neuropathic pain.

Temporary vs permanentStudy designs include temporary percutaneous lead treatment (eg, 60 days) with leads removed after trial, and permanent implants for selected responders.

Responder thresholdsTrials commonly defined responders as those achieving ≥50% pain reduction during the treatment window used to determine therapeutic effect.

inv-143: Percutaneous Peripheral Nerve Stimulation (PNS) — definition

PNS summaryMinimally invasive implantation or percutaneous lead placement near peripheral nerves to deliver analgesic stimulation for peripheral nerve–origin pain.

Evidence characterEvidence consists of small RCTs, case series, and observational studies with generally low to very low strength; larger controlled trials recommended.

Common endpointsPain intensity reduction (30–50% thresholds), functional improvements, and opioid-sparing effects are typical outcomes measured in studies.

inv-144: Pulsed Electromagnetic Field (PEMF) / Pulsed Electrical Stimulation (PES) — definition

PEMF/PES definitionNoninvasive therapies applying pulsed electromagnetic or electrical fields intended to modulate pain, inflammation, or tissue healing.

Treatment heterogeneityParameters and durations vary widely across trials (eg, 10 days to 6 weeks); subgroup analyses often separate <4 weeks vs 4–6 weeks regimens.

Evidence statementSystematic reviews report mixed results with some short‑term benefits for pain/stiffness in OA and CLBP, but long‑term efficacy remains uncertain.

inv-145: Restorative Neurostimulation — implantable stimulation targeting paraspinal muscles

DefinitionImplantable stimulation targeting paraspinal (multifidus) muscles to restore motor control and relieve chronic low back pain associated with multifidus dysfunction.

Device exampleReActiv8 system delivers scheduled stimulation to bilateral L2 medial branch to rehabilitate multifidus function.

Indication contextUsed for intractable mechanical CLBP after failure of conservative therapies and when imaging/physiological testing supports multifidus dysfunction.

inv-146: Restorative neurostimulation (ReActiv8) — device definition and intent

ReActiv8 definitionAn implantable neuromuscular stimulator indicated for bilateral stimulation of the L2 medial branch for adults with intractable CLBP associated with multifidus dysfunction; PMA approved.

Therapy deliveryScheduled, twice‑daily stimulation sessions following implantation with programed activation and long‑term follow‑up in trials.

Candidate criteriaRCT eligibility included >90 days of medical management and at least one course of physical therapy prior to implantation.

inv-147: Scrambler therapy (ST) — definition and typical treatment course

Scrambler therapy definitionA transcutaneous electrical modulation technique (also called TEMPR/Calmare) intended to modulate pain signaling with typical treatment sessions of ~30–50 minutes/day over about 10 working days.

Treatment courseTypical protocols in trials: daily sessions (30–50 minutes) across ~10 consecutive working days with follow-up to three months in many studies.

Evidence cautionSystematic reviews note low study quality and inconsistent results; major oncology guidelines do not recommend routine use for CIPN outside trials.

inv-148: Scrambler Therapy (ST) — TENS-type device cleared by FDA (Product Code GZJ)

Regulatory noteScrambler Therapy (Calmare/ST MC-5A and ST-5A) is a TENS-type device cleared by FDA (Product Code GZJ) with multiple 510(k) clearances documented.

Guideline stanceDespite FDA clearances, guideline evidence (eg, ASCO, ESMO/EONS/EANO) finds insufficient support for routine use in CIPN.

Protocol reminderTrials commonly used daily 30–50 minute sessions over ~10 days; exact device settings varied by study generation.

inv-149: Restorative Neurostimulation (ReActiv8) — implantable neuromuscular stimulator definition

ReActiv8 indicationImplantable neuromuscular stimulator indicated for bilateral L2 medial branch stimulation in adults with intractable CLBP associated with multifidus dysfunction; PMA approved (June 16, 2020).

Intended populationAdults who have failed therapy including medications and physical therapy and are not candidates for spine surgery, with imaging or physiological evidence of multifidus dysfunction.

Regulatory referenceDevice PMA information is available (Product Code QLK) and trial evidence includes randomized sham‑controlled and long‑term follow‑ups.

inv-150: PoNS / TLNS — portable neuromodulation stimulator delivering tongue stimulation

PoNS/TLNS definitionA nonimplantable portable neuromodulation stimulator delivering stimulation to the tongue (translingual) studied as an adjunct to targeted physical therapy for gait/balance deficits.

Approved usePoNS De Novo approval indicates adjunct short‑term treatment of gait deficit in mild‑to‑moderate MS for adults ≥22 years alongside supervised therapeutic exercise.

Trial contextRCTs combined PoNS/TLNS with PT over 5–14 week courses with automatic device adherence logging reported in some studies.

inv-151: Scrambler Therapy (ST) — device family with FDA clearances and clearance history

Scrambler device familyCalmare/ST MC-5A and ST-5A are TENS‑like devices with FDA 510(k) clearances and replacement devices documented; trial generations vary across studies.

Evidence cautionMeta-analyses report marginal pain decreases and low methodological quality across RCTs; guideline bodies recommend use primarily in clinical trials for CIPN.

Typical protocolCommon study protocol: daily sessions (30–50 minutes) over ~10 working days with follow-up to 3 months in many RCTs.

inv-152: Transcutaneous Electrical Nerve Stimulator (TENS) — definition and regulatory note

TENS regulatory statusClass II FDA‑regulated devices for transcutaneous electrical nerve stimulation; numerous products fall under product codes such as GZJ, NUH, and NGX.

Device familyIncludes conventional TENS, MENS-classified devices, and devices marketed for pain modulation across multiple indications.

Clinical roleOften used as conservative, noninvasive first‑line electrotherapy or as adjunct to rehabilitation programs depending on indication and guideline recommendations.

inv-153: Translingual Stimulation (TLS) / PoNS — De Novo approval and intended use

PoNS regulatory statusPoNS (Portable Neuromodulation Stimulator) granted De Novo approval (March 25, 2021) for adjunct short‑term treatment of gait deficit in mild‑to‑moderate MS in patients ≥22 years, by prescription and alongside supervised therapeutic exercise.

Intended deliveryNonimplantable translingual stimulation delivered via a mouthpiece combined with supervised PT protocols in RCTs of 5–14 week duration.

Evidence noteECRI and RCTs found improvements when combined with PT, but overall evidence inconclusive and often from same research centers; larger independent trials recommended.

inv-154: NICE guidance — National Institute for Health and Care Excellence guidelines cited

NICE guidance referencedNICE guidelines cited include chronic pain (NG193), low back pain and sciatica (NG59), osteoarthritis (NG226), and rehabilitation guidelines relevant to electrotherapy use.

Guideline implicationSeveral NICE recommendations advise caution or against routine use of certain electrotherapies (eg, IFT/PENS for specific LBP/OA indications) due to insufficient evidence.

Reviewer actionPolicy reviewers should consult referenced NICE guidance when aligning coverage decisions with guideline-based recommendations.

Imaging, Testing, and Objective Assessment Requirements

Documentation Required

Restorative neurostimulation implantation: medial branch lead placement

Implantation of restorative neurostimulation involves placement of self‑anchoring leads next to the medial branch of the dorsal ramus; documentation of appropriate targeting and implanting clinician expertise is implied.

Documentation Required

Document objective outcome assessments (eg, VFSS, MRI) as clinically indicated

When NMES is used for dysphagia or other indications that require objective outcome assessment, include appropriate tests such as VFSS for dysphagia or MRI for muscle volume as clinically indicated.

VFSS for dysphagia
MRI for muscle volume

Note

MENS monitoring (research): musculoskeletal ultrasound reported

Musculoskeletal ultrasound was used in an MENS trial to assess effusion changes in research settings; imaging monitoring may be reported in trials but is not routinely specified for clinical care.

Note

No routine MENS imaging requirements specified

Routine monitoring or imaging requirements for MENS are not specified in the reviewed evidence; studies reported variable use of imaging as outcomes rather than mandated clinical requirements.

Documentation Required

PNS lead placement: imaging/guidance implied

PNS lead placement targeted to specific peripheral nerves in trials implies use of imaging or guidance (eg, fluoroscopy/ultrasound) though explicit imaging mandates are not specified in this excerpt.

Note

No uniform imaging requirements specified across studies

Individual studies report implantation and follow‑up imaging or testing but this policy excerpt does not mandate specific imaging requirements for most devices; review study protocols for required assessments.

Note

Restorative neurostimulation: no additional imaging requirements specified

No specific imaging requirements for restorative neurostimulation implantation are described in this excerpt beyond implantation targeting and clinical selection criteria.

Documentation Required

ReActiv8 candidacy: imaging/physiologic testing to demonstrate multifidus dysfunction

ReActiv8 implant indication references imaging or physiological testing to demonstrate multifidus dysfunction; documentation of such testing is expected when claiming device candidacy.

Note

No imaging mandates for other devices in this excerpt

No specific imaging requirements are described for other devices in this excerpt; providers should follow device trial protocols or plan requirements for any imaging documentation.

Background and Scope

Electrical stimulation therapies encompass a broad range of modalities including surface devices (TENS, NMES), percutaneous techniques (PENS, PENFS), peripheral implanted systems (PNS, PSFS), restorative implanted neurostimulation (e.g., multifidus stimulation/ReActiv8), and functional electrical stimulation (FES) used to elicit task‑related movements. These modalities are applied across indications such as pain modulation, prevention of disuse atrophy, gait rehabilitation, and restoration of motor control, with the evidence base varying substantially by modality and indication.

Not Covered / Exclusions (Extracted)

The policy explicitly identifies home‑based FES for SCI as not supported by sufficient peer‑reviewed evidence and lists it among therapies not covered when used for rehabilitation without stronger published data. Other implantable‑electrode FES applications with very low‑quality evidence are also noted as potential exclusions.

Policy Revision History

2026-01-01template_updateLatest

Created shared policy version to support application to Oxford plan membership; updated policy template.

2026-01-01coding_update

Applicable CPT code list updated: added CPT code 64567.

2026-01-01coding_update

Applicable CPT code list updated: removed temporary code 0720T.

2026-01-01archival

Archived previous policy version 2025T0126SS in policy history.